FDA APPROVES TILTAN’S INVESTIGATIONAL NEW DRUG (IND) CLINICAL TRIAL PROGRAM 21.12.2010 Jerusalem, Israel – December 21, 2010 - - Tiltan Pharma Ltd. is pleased to announce it has received a favourable review from the U.S. FDA which will allow for the launch a of U.S. based clinical study using Tiltan’s emerging strategy for cancer treatment, a patented, mechanism based designed anti-angiogenic drug combination using FDA approved drugs that target different, non-overlapping pathways of the angiogenic process. Tiltan is conducting an FDA approved Phase IIb global clinical study for Castration Resistant Prostate Cancer (“CRPC”) which will be based in Israel, Russia and the United States. The focus of the study will be on safety and efficacy of Tiltan’s anti—angiogenic drug combination. Israeli trials are currently underway and now that FDA approval has been granted Tiltan intends to expand the study to the United States at Johns Hopkins in Baltimore, Maryland “We are very pleased to announce the U.S. launch of the Phase IIb study for CRPC and look forward to extending the encouraging data we have compiled to date in a formal manner through this study”, said Dr. Dan Goldstaub, Tiltan’s Chief Operating Officer. Tiltan, founded in 2005 and derived from Hebrew University’s technology transfer division, Yissum, has raised approximately $3 million since 2005 from a group of high net worth investors in both Israel and Canada as well as having been awarded an additional $2 million from the Office of the Chief Scientist of Israel. To date, the company has successfully demonstrated, through a Phase I and IIa clinical study, both safety and tolerability for patients with various indications of solid tumors, including Prostate, Ovarian and Sarcomas. About Tiltan Pharma Tiltan Pharma Ltd. is dedicated to the development and commercialization of a proprietary anti-angiogenic platform for the treatment of cancer and other indications. Tiltan’s proprietary anti-cancer platform is based on a combination of agents that target different, non-overlapping aspects of the angiogenic process. All of these agents are orally bio-available and FDA approved.